The Pharma Data

AUGUST 3, 2021

The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads. The research team, including scientists from the U.S.

Virus 52

Virus Clinical Trials Drugs Laboratories 52

Science Daily: Pharmacology News

NOVEMBER 9, 2023

Using an accelerated arms race between bacteria and viruses, researchers are documenting rapid evolutionary processes in simple laboratory flasks in only three weeks. Rather than a slow, gradual process as Darwin envisioned, biologists can now see how evolutionary changes unfold on much more accelerated timescales.

Virus 45

Virus Laboratories Research 45

The Pharma Data

JUNE 26, 2021

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection. However, the discovery does show that the virus can change in unexpected ways and find new ways to cause infection. Now, researchers at Washington University School of Medicine in St.

Virus 52

Virus Cell Biology Vaccine Research 52

NIH Director's Blog: Drug Discovery

NOVEMBER 5, 2020

Because SARS-CoV-2 is so highly infectious, basic researchers without access to specially designed biosafety facilities may be limited in their ability to study the virus. While the quantum dots may bind and enter human cells just like the virus, they can’t cause an infection. Naval Research Laboratory (Washington, D.C.)

Research Laboratories 85

Research Laboratories Laboratories Science Drugs 85

Drug Target Review

APRIL 17, 2024

Dr Chowell spent a year as a visiting graduate student at the Moe Win Laboratory for Information and Decision Systems at MIT. During residency, he conducted laboratory research with Dr Timothy Chan investigating predictors of response to immunotherapy as part of the American Board of Radiology Holman Research pathway.

Immune Response 105

Immune Response Laboratories DNA Virus 105

Codon

AUGUST 26, 2024

Brian Wang (co-founder of the nonprofit Panoplia Laboratories ) outlines his approach to making broad-spectrum antivirals. When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use.

RNA 85

RNA Virus DNA Vaccine 85

BMG Labtech

MARCH 11, 2024

Enzyme-Linked Immunosorbent Assays (ELISAs) are an essential technique in today’s laboratory with many applications in the life sciences. 1,2 Anton Schuurs and Bauke van Weemen at the research laboratories of NV Organon, Oss, the Netherlands developed a similar technique which was also published in 1971.

Vaccine 98

Vaccine Molecular Biology Laboratories Virus 98

Broad Institute

AUGUST 31, 2023

Now researchers at the Broad Institute of MIT and Harvard have used cutting-edge continuous laboratory evolution and engineering methods to develop improved versions of the gene-editing tool. What had not been done until now is improving the reverse transcriptase in a way that’s tailor-made for prime editing.”

DNA 145

DNA RNA Engineering Laboratories 145

Drug Target Review

JANUARY 26, 2024

Researchers from Columbia University and the US Department of Energy (DOE)’s Brookhaven National Laboratory have elucidated a method to produce large quantities of the receptor that the SARS-CoV-2 spike protein uses to bind to the surface of human cells.

Production 114

Production DNA Virus Protein Expression 114

Agency IQ

JULY 26, 2024

reference laboratories for high-risk diagnostics The newly available May 2024 meetings of the Medical Device Coordination Group provide insight into the European Commission’s efforts to fully implement the European medical device and diagnostic regulations. Reference Laboratories: E.U. Top IVDR Notified Body concern: Lack of E.U.

Laboratories 40

Laboratories Regulations Virus Production 40

Broad Institute

MAY 14, 2024

William Studier for development of widely used protein- and RNA-production platform The $400,000 award recognizes the far-reaching medical impacts of Studier’s development, in the 1980s, of an efficient and scalable technology to produce mass amounts of RNA and proteins in laboratories that is widely used today all over the world.

RNA 84

RNA Production Molecular Biology Laboratories 84

Codon

AUGUST 27, 2024

While reading all the sequences present in a sample, researchers want to find any that are out of place, such as those that belong to a never-before-seen virus. At least nine laboratories outside the U.S. Federally funded laboratories must also deposit genetic sequences into public databases, such as GISAID and GenBank.

DNA 84

DNA Laboratories Hospitals Virus 84

The Pharma Data

NOVEMBER 27, 2020

UK firm develops solution for identifying whether patients are actually infectious from a virus or not. Iceni Diagnostics has revealed it is developing a new technology that can disclose if patients are actually infectious with a live virus or not. Read on to for the full insight.

Vaccine 52

Vaccine Virus International Immune Response 52

The Pharma Data

JANUARY 6, 2021

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ sangivamycin) has broad-spectrum antiviral activity in laboratory-based assays against several viruses. ROCHESTER, N.Y. , 7, 2021 /PRNewswire/ — OyaGen, Inc. Bennett et al., About OYA1. OYA1 (a.k.a.

Virus 40

Virus Clinical Trials Government Laboratories 40

addgene Blog

MAY 30, 2023

Adeno-associated virus (AAV) is a single stranded, Parvoviridae DNA virus, packaged in a non-enveloped icosahedral capsid, that can be used to express genes of interest in cell and animal models. This post was contributed by guest blogger Didem Goz Ayturk with edits and updates from Addgenies Karen Guerin and Susanna Stroik.

Virus 53

Virus Packaging DNA Laboratories 53

Drug Target Review

DECEMBER 5, 2024

Challenges of viral capsids in gene therapy efficiency A widely used production method of rAAV vectors requires co-transfection of host cell lines with three plasmids, including one carrying the transgene of interest, one carrying the capsid and replication sequences, and a helper virus to circumvent the inability of rAAV to self-amplify.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

SEPTEMBER 17, 2020

A rapid test can accurately diagnose a coronavirus infection within 90 minutes without needing a specialist laboratory, say scientists. The device is already being used in eight NHS hospitals to quickly identify patients who are carrying the virus. ” If the lab tests said the patient was free of the virus, so did the rapid test.

Virus 52

Virus Laboratories Hospitals Research 52

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Medical Schools Virus Science 137

Broad Institute

JUNE 27, 2024

They used an engineered adeno-associated virus (AAV) that crosses the blood-brain barrier after intravenous administration. However, with a strong therapy design and promising laboratory results in hand, the researchers have good reason to be hopeful.

Disease 142

Disease Therapies Engineering Clinical Trials 142

SCIENMAG: Medicine & Health

OCTOBER 18, 2023

This study is conducted by the Jiangsu Provincial Center for Disease Control and Prevention, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Vaccines for Infectious Diseases of Xiamen University, China National Institutes for Food and Drug Control, and Xiamen Innovax Biotech Company.

Vaccine 52

Vaccine Laboratories Virus Science 52

The Pharma Data

MARCH 20, 2021

As laboratories around the world tackle the challenges of screening large numbers of samples for SARS-CoV-2, the managers of these labs have turned to the use of automation to address some key concerns. As there are fewer steps carried out by hand this reduces potential exposure for laboratory staff as well. In the examples below, we.

Laboratories 52

Laboratories Virus RNA Bioinformatics 52

Drug Target Review

DECEMBER 6, 2023

Chapter 2 explores immuno-oncology, emphasising the significance of robust T cells, the potential of cytokines IL-12 and IL-18, and the innovative use of CAR T-cell methods against the SARS-CoV-2 virus.

Research 64

Research Pharmacy Vaccine Laboratories 64

The Pharma Data

JANUARY 26, 2021

offered its genomics expertise to identify emerging variants of the SARS-CoV-2 virus to countries that lack the resources to make such identifications. The plan dovetails with the Chatham House Sustainable Laboratories Initiative , announced in 2019. On Tuesday, the U.K. The offer came as part of the U.K.’s South Africa and Brazil.

Virus 52

Virus Vaccine Laboratories International 52

PerkinElmer

MAY 28, 2020

Unfortunately, the road towards treatment can be time-consuming, especially when utilizing assays with live virus. The handling of these pathogens needs to take place in research laboratories that are designated as biosafety level 3 or higher due to its dangerous infectious nature.

Vaccine 52

Vaccine Disease Virus Small Molecule 52

The Pharma Data

APRIL 15, 2022

Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. The top protein neutralized the virus with similar or greater potency than antibody treatments with Emergency Use Authorization status from the U.S.

Treatment 52

Treatment Virus Laboratories Engineering 52

PerkinElmer

JULY 13, 2020

The complex relationship between a virus and its host is one of the hottest topics in science right now, and has been given considerable attention in recent weeks as a result of the race to understand the virus that causes COVID-19 and its potential vulnerabilities.

RNA 52

RNA Virus Laboratories Science 52

The Pharma Data

DECEMBER 10, 2020

Unsupervised use of this technique by people without medical training can lead to transmission of pathogens, according to Paul Carlson, principal investigator in the Laboratory of Mucosal Pathogens and Cellular Immunology at FDA’s Office of Vaccines Research and Review. 1, 2019, until effective screening methods are implemented.”.

FDA 52

FDA Laboratories RNA Virus 52

Codon

DECEMBER 12, 2024

Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine. A mirrored organism would use right-handed molecules everywhere a naturally-occurring organism uses left-handed ones, and vice versa.

DNA 99

DNA RNA Vaccine Virus 99

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. The research team, led by Yan Wu, Capital Medical University, Beijing, first isolated the pair of antibodies in the laboratory, starting with white blood cells from the patient.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

JANUARY 14, 2021

1.351 variants with a short turn-around time, ideal for retesting millions of positive samples to detect if the virus is the B.1.1.7 NovaType is already available as a Laboratory Developed Test (LDT) in Germany and will shortly be made available to the more than 50 Eurofins laboratories worldwide testing patients for COVID-19.

Laboratories 52

Laboratories Virus Vaccine FDA 52

The Pharma Data

NOVEMBER 18, 2020

HIV drug resistance is caused by changes in the genetic structure of HIV that affects the ability of drugs to block the replication of the virus. Map: WHO HIV drug resistance laboratory network. These laboratories are members of the WHO HIVResNet and function under the WHO HIV drug resistance Laboratory Operational Framework.

Laboratories 52

Laboratories Therapies Virus Government 52

The Pharma Data

FEBRUARY 25, 2022

“There remains an urgent need for SARS-CoV-2 therapeutic agents that target parts of the virus other than the spike protein that are not as likely to evolve.” Pell ABSL-3 Laboratory for Advanced Biological Research at Penn State, and discovered that eight of them had dose-dependent antiviral activities against SARS-CoV-2.

FDA Approval 52

FDA Approval Molecular Biology FDA Virus 52

The Pharma Data

MARCH 9, 2022

Scientists found the substance stopped SARS-CoV-2, the virus that causes COVID-19, from reproducing itself and also protected infected cells when tested in human lung cells. Few treatments currently exist for COVID-19 and the ones that do primarily focus solely on preventing the virus from replicating.

Treatment 52

Treatment Virus Engineering Therapies 52

The Pharma Data

MARCH 20, 2021

Accurate and timely laboratory diagnosis of COVID-19 is one of the most pivotal requirements for optimal disease management and contact tracing. The vast majority of current laboratory testing for COVID-19 is based either on detection of viral antigens, nucleic acids or on detection of virus-specific antibodies in the sera of patients.

Virus 52

Virus Assay Development Laboratories RNA 52

The Pharma Data

NOVEMBER 26, 2020

Researchers at Heidelberg University in Germany performed detailed imaging analysis to determine how SARS-CoV-2, the virus that causes COVID-19, reprograms infected cells. The virus causes changes in the membrane so it can produce its own replication organelles, amplifying the viral genome. It only takes 24 to 48 hours.

Research 52

Research Virus Vaccine DNA 52

The Pharma Data

MARCH 16, 2021

The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission. Among them, mutations E484K, N501Y and del 69-70 are located in the spike protein, the region that enables the virus to attach to and enter the human cell. 1.1.7), South Africa (B.1.351),

Clinical Trials 52

Clinical Trials Laboratories Virus Vaccine 52